Metronomic Chemotherapy in Female Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 14 February 2026 | Viewed by 245
Special Issue Editor
Interests: COVID-19; SARS; MERS; Middle East respiratory syndrome-coronavirus (MERS-CoV); ebola virus disease; marburg virus disease; nipah virus (NIV); human papilloma virus (HPV); HPV test; pap smear; gynecological pathology; hemolymphopathology; lymphoma; leukemia; herpes simplex virus; cytomegalovirus (CMV)
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to announce a call for submissions for a Special Issue of Cancers on the theme of "Metronomic Chemotherapy in Female Cancers". Metronomic chemotherapy, characterized by the frequent administration of low doses of chemotherapeutic agents without extended drug-free breaks, has shown promise in the treatment of various female cancers.
This Special Issue will showcase research articles and reviews that delve into the efficacy, mechanisms, and clinical implications of metronomic chemotherapy in female malignancies. We invite contributions that explore, but are not limited to, the following topics:
- The evaluation of metronomic chemotherapy in breast cancer, ovarian cancer, cervical cancer, and other female-specific malignancies;
- Mechanistic insights into the anti-tumor effects of metronomic chemotherapy agents;
- Clinical trials and outcomes associated with metronomic chemotherapy regimens in female cancer patients;
- Combination therapies incorporating metronomic chemotherapy for enhanced treatment outcomes;
- Challenges and future directions in the application of metronomic chemotherapy in female cancers.
All submissions will undergo rigorous peer review to confirm their scientific value and relevance to the field. We encourage submissions from researchers, oncologists, pharmacologists, and other experts engaged in the management of female cancer patients.
By sharing research and clinical experiences on metronomic chemotherapy in female cancers, this Special Issue will advance our understanding of this treatment modality and its potential impacts on patient care. Your contributions are vital in shaping the discourse around metronomic chemotherapy in the context of female cancers.
If you have any enquiries or require additional information or assistance, please do not hesitate to reach out to us. We are committed to facilitating your participation in this Special Issue and look forward to receiving your valuable submissions.
Thank you for your time and attention in reading this announcement. We are excited to receive insightful contributions from the research community.
Warm regards,
Prof. Dr. Luca Roncati
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metronomic chemotherapy
- female cancers
- anti-tumor mechanisms
- clinical trials and outcomes
- combination therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
